Compare BridgeBio Pharma Inc (BBIO) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs LTC Properties Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while LTC Properties Inc trades at $38.12 (market cap $2.12B). The key difference: BridgeBio Pharma Inc is far larger — about 7.8× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.78% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | LTC | |
|---|---|---|
Market Cap | $16.61B | $2.12B |
Sector | Health | Real Estate |
52-Week High | $90.17 | $42.81 |
52-Week Low | $47.29 | $33.98 |
Enterprise Value | $18.16B | $2.86B |
Dividend Yield | — | 5.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LTC Properties trades at $39.85, up 1.01% today, with a bullish technical signal supported by moving averages. The REIT shows strong fundamentals with a 14.08 P/E ratio, 38.93% net income margin, and consistent dividend payments of $0.19 monthly. Recent acquisitions in seniors housing (SHOP) portfolio total $285 million year-to-date, driving revenue growth from $210M in 2024 to $263M in 2025. However, earnings misses in two of the last three quarters and rising debt-to-asset ratio to 42.64% warrant caution.
Outlook remains positive due to demographic tailwinds in senior housing and aggressive SHOP expansion, but investors face risks from execution challenges in acquisitions and interest rate sensitivity. Analyst consensus is mixed with 27% buy ratings versus 59% hold, suggesting cautious optimism amid transition phase.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
